8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 17, 2026·SEC
Bicycle Therapeutics plc(BCYC)Earnings, Financials & Key Ratios
BCYC•NASDAQ
$4.90
$339M mkt cap·Price updated May 6, 2026
AboutBicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Show more
- Revenue$73M+105.8%
- EBITDA-$241M-19.0%
- Net Income-$219M-29.5%
- EPS (Diluted)-3.16-9.0%
- Gross Margin100%+125.6%
- EBITDA Margin-332.43%+42.1%
- Operating Margin-341.28%+42.6%
- Net Margin-301.66%+37.0%
- ROE-31.21%-7.5%
- Debt/Equity0.03+140.0%
- Interest Coverage-1061.17-966.9%
BCYC Key Insights
Bicycle Therapeutics plc (BCYC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 47.5%
- ✓Trading at only 0.6x book value
✗Weaknesses
- ✗Profits declining 33.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 14 (bottom 14%)
- ✗Shares diluted 19.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BCYC Price & Volume
Bicycle Therapeutics plc (BCYC) stock price & volume — 10-year historical chart
Loading chart...
BCYC Growth Metrics
Bicycle Therapeutics plc (BCYC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years47.52%
3 Years71.21%
TTM146.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-7.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-0.64%
Return on Capital
10 Years-47.45%
5 Years-31.27%
3 Years-34.88%
Last Year-31.96%
BCYC Recent Earnings
Bicycle Therapeutics plc (BCYC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026EPS
$0.87
Est $0.62
-40.1%
Revenue
$893,500
Est $8M
-88.1%
Q2 2026
Mar 17, 2026EPS
$0.29
Est $0.94
+69.1%
Revenue
$48M
Est $7M
+581.6%
Q4 2025
Oct 30, 2025EPS
$0.85
Est $1.09
+22.0%
Revenue
$12M
Est $7M
+65.8%
Q3 2025
Aug 8, 2025EPS
$1.14
Est $0.95
-20.0%
Revenue
$3M
Est $8M
-65.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.87vs $0.62-40.1% | $893,500vs $8M-88.1% |
| Q2 2026 | Mar 17, 2026 | $0.29vs $0.94+69.1% | $48Mvs $7M+581.6% |
| Q4 2025 | Oct 30, 2025 | $0.85vs $1.09+22.0% | $12Mvs $7M+65.8% |
| Q3 2025 | Aug 8, 2025 | $1.14vs $0.95-20.0% | $3Mvs $8M-65.2% |
Based on last 12 quarters of dataView full earnings history →
BCYC Peer Comparison
Bicycle Therapeutics plc (BCYC) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PEPG | 132.93M | 1.93 | -0.91 | -75.73% | 0.12 | |||
 CYCN | 13.64M | 3.15 | -2.89 | 3.7% | -170.11% | -39.23% | ||
 PRAX | 7.5B | 333.30 | -24.73 | -100% | -58.74% | 0.00 | ||
 TERN | 4.64B | 52.97 | -47.29 | -29.95% | 0.00 | |||
 AGIO | 1.62B | 27.21 | -3.82 | 48.03% | -6.4% | -34.11% | 0.05 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 5.7B | 36.10 | 240.67 | 40.8% | 13.31% | 21.87% | 1.14 |
Compare BCYC vs Peers
Bicycle Therapeutics plc (BCYC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCYC Income Statement
Bicycle Therapeutics plc (BCYC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.06M | 7.14M | 13.8M | 10.39M | 11.7M | 14.46M | 26.98M | 35.27M | 72.59M | 63.5M |
| Revenue Growth % | - | 246.41% | 93.4% | -24.72% | 12.58% | 23.65% | 86.52% | 30.76% | 105.77% | 146.85% |
| Cost of Goods Sold | 11.87M | 20.76M | 25.54M | 33.15M | 0 | 0 | 156.5M | 172.97M | 0 | 71.03M |
| COGS % of Revenue | 576.02% | 290.93% | 185.06% | 319.05% | - | - | 580.13% | 490.34% | - | - |
| Gross Profit | -9.81M▲ 0% | -13.63M▼ 38.9% | -11.74M▲ 13.8% | -22.76M▼ 93.9% | 11.7M▲ 151.4% | 14.46M▲ 23.6% | -129.52M▼ 995.5% | -137.69M▼ 6.3% | 72.59M▲ 152.7% | -8.42M▲ 0% |
| Gross Margin % | -476.02% | -190.93% | -85.06% | -219.05% | 100% | 100% | -480.13% | -390.34% | 100% | -13.26% |
| Gross Profit Growth % | -3541.44% | -38.95% | 13.84% | -93.88% | 151.4% | 23.65% | -995.53% | -6.31% | 152.72% | - |
| Operating Expenses | 18.27M | 28.88M | 14.56M | 29.2M | 77.31M | 131.12M | 60.43M | 72.18M | 320.3M | 234.76M |
| OpEx % of Revenue | 887.04% | 404.74% | 105.5% | 281.05% | 660.98% | 906.56% | 224% | 204.62% | 441.28% | - |
| Selling, General & Admin | 6.41M | 8.12M | 14.56M | 29.2M | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M | 76.56M |
| SG&A % of Revenue | 311.02% | 113.8% | 105.5% | 281.05% | 277.29% | 342.3% | 221.8% | 202.59% | 110.24% | - |
| Research & Development | 11.87M | 20.76M | 31.64M | 33.15M | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M | 230.13M |
| R&D % of Revenue | 576.02% | 290.93% | 229.26% | 319.05% | 383.69% | 564.26% | 580.13% | 490.34% | 331.03% | - |
| Other Operating Expenses | -119K | -665K | -31.64M | -33.15M | 0 | 0 | -155.9M | -172.25M | 0 | -1.16M |
| Operating Income | -16.21M▲ 0% | -21.75M▼ 34.1% | -26.3M▼ 20.9% | -51.96M▼ 97.6% | -65.62M▼ 26.3% | -116.65M▼ 77.8% | -189.95M▼ 62.8% | -209.87M▼ 10.5% | -247.72M▼ 18.0% | -242.29M▲ 0% |
| Operating Margin % | -787.04% | -304.74% | -190.56% | -500.1% | -560.98% | -806.56% | -704.13% | -594.96% | -341.28% | -381.59% |
| Operating Income Growth % | -20.15% | -34.13% | -20.94% | -97.57% | -26.29% | -77.78% | -62.83% | -10.49% | -18.03% | - |
| EBITDA | -15.88M | -21.04M | -25.34M | -50.68M | -64.21M | -112.96M | -183.4M | -202.69M | -241.3M | -237.5M |
| EBITDA Margin % | -770.75% | -294.78% | -183.6% | -487.81% | -548.94% | -781.06% | -679.86% | -574.61% | -332.43% | -374.05% |
| EBITDA Growth % | -20.06% | -32.48% | -20.46% | -100.02% | -26.69% | -75.93% | -62.35% | -10.52% | -19.04% | 5.43% |
| D&A (Non-Cash Add-back) | 335.56K | 710.8K | 960K | 1.28M | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M | 4.79M |
| EBIT | -16.21M | -22.24M | -26.3M | -51.96M | -65.5M | -110.9M | -189.95M | -172.07M | -218.6M | -156.81M |
| Net Interest Income | 50K | 169K | 814K | 226K | -2.86M | 2.41M | 10.74M | 32.55M | 28.26M | 13.19M |
| Interest Income | 50K | 169K | 814K | 683K | 120K | 5.76M | 14M | 34.28M | 28.46M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 457K | 2.98M | 3.34M | 3.26M | 1.73M | 206K | 107K |
| Other Income/Expense | -69K | -496K | -4.56M | 226K | -2.86M | 2.41M | 10.74M | 36.08M | 28.91M | 24.67M |
| Pretax Income | -16.28M▲ 0% | -22.24M▼ 36.6% | -30.86M▼ 38.8% | -51.73M▼ 67.6% | -68.48M▼ 32.4% | -114.24M▼ 66.8% | -179.21M▼ 56.9% | -173.8M▲ 3.0% | -218.81M▼ 25.9% | -217.62M▲ 0% |
| Pretax Margin % | -790.39% | -311.69% | -223.62% | -497.92% | -585.47% | -789.88% | -664.32% | -492.69% | -301.45% | -342.73% |
| Income Tax | -23K | -396K | -254K | -724K | -1.66M | -1.52M | 1.46M | -4.76M | 152K | 1.41M |
| Effective Tax Rate % | 0.14% | 1.78% | 0.82% | 1.4% | 2.43% | 1.33% | -0.81% | 2.74% | -0.07% | -0.65% |
| Net Income | -16.26M▲ 0% | -21.85M▼ 34.4% | -30.61M▼ 40.1% | -51.01M▼ 66.7% | -66.82M▼ 31.0% | -112.72M▼ 68.7% | -180.66M▼ 60.3% | -169.03M▲ 6.4% | -218.96M▼ 29.5% | -219.03M▲ 0% |
| Net Margin % | -789.27% | -306.14% | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -479.18% | -301.66% | -344.95% |
| Net Income Growth % | -20.34% | -34.36% | -40.11% | -66.66% | -30.99% | -68.69% | -60.28% | 6.44% | -29.54% | -7.78% |
| Net Income (Continuing) | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M | -218.96M | -219.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.22▲ 0% | -1.64▼ 34.4% | -2.77▼ 68.9% | -2.66▲ 4.0% | -2.67▼ 0.4% | -3.80▼ 42.3% | -5.08▼ 33.7% | -2.90▲ 42.9% | -3.16▼ 9.0% | -3.14▲ 0% |
| EPS Growth % | -60.53% | -34.43% | -68.9% | 3.97% | -0.38% | -42.32% | -33.68% | 42.91% | -8.97% | -0.64% |
| EPS (Basic) | -1.22 | -1.64 | -2.77 | -2.66 | -2.67 | -3.80 | -5.08 | -2.91 | -3.16 | - |
| Diluted Shares Outstanding | 13.29M | 13.29M | 11.05M | 19.15M | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M | 69.68M |
| Basic Shares Outstanding | 13.29M | 13.29M | 11.05M | 19.15M | 25.06M | 29.66M | 35.59M | 58.21M | 69.28M | 69.68M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCYC Balance Sheet
Bicycle Therapeutics plc (BCYC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 71.51M | 76.77M | 104.15M | 155.72M | 458.56M | 369.38M | 561.87M | 928.61M | 628.11M | 619.13M |
| Cash & Short-Term Investments | 67.66M | 63.38M | 92.12M | 135.99M | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M | 559.47M |
| Cash Only | 67.66M | 63.38M | 92.12M | 135.99M | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M | 559.47M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 3M | 11.31M | 7.14M | 14.63M | 11.91M | 21.21M | 24.04M | 35.65M | 35.59M | 0 |
| Days Sales Outstanding | 531.73 | 578.65 | 188.97 | 514.06 | 371.65 | 535.2 | 325.26 | 368.91 | 178.99 | 235.12 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 9.02M | 11.41M | 13.43M | -35.59M | 59.66M |
| Total Non-Current Assets | 2.49M | 4.86M | 6.05M | 5.43M | 21.24M | 41.23M | 33.48M | 28.26M | 89.49M | 33.26M |
| Property, Plant & Equipment | 1.36M | 1.82M | 4.35M | 3.61M | 17.79M | 32.77M | 27.68M | 17.19M | 0 | 20.27M |
| Fixed Asset Turnover | 1.51x | 3.93x | 3.17x | 2.88x | 0.66x | 0.44x | 0.97x | 2.05x | - | 5.54x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 547K | 547K | 58K | 605K |
| Other Non-Current Assets | 1.13M | 3.04M | 1.7M | 1.82M | 3.45M | 8.46M | 5.24M | 10.53M | 89.43M | 129.4M |
| Total Assets | 74M▲ 0% | 81.63M▲ 10.3% | 110.19M▲ 35.0% | 161.15M▲ 46.2% | 479.79M▲ 197.7% | 410.61M▼ 14.4% | 595.34M▲ 45.0% | 956.87M▲ 60.7% | 717.6M▼ 25.0% | 652.4M▲ 0% |
| Asset Turnover | 0.03x | 0.09x | 0.13x | 0.06x | 0.02x | 0.04x | 0.05x | 0.04x | 0.10x | 0.09x |
| Asset Growth % | 525.27% | 10.3% | 35% | 46.24% | 197.73% | -14.42% | 44.99% | 60.73% | -25.01% | -95.85% |
| Total Current Liabilities | 9.45M | 8.93M | 8.82M | 23.13M | 36.24M | 53.34M | 69.54M | 67.23M | 56.98M | 48.89M |
| Accounts Payable | 2.06M | 1.89M | 1.95M | 1.36M | 2.72M | 6.47M | 13.05M | 15.79M | 9.67M | 5.97M |
| Days Payables Outstanding | 63.52 | 33.18 | 27.85 | 15.03 | - | - | 30.44 | 33.33 | - | 59.81 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.88M | 0 | 2.76M | 0 |
| Deferred Revenue (Current) | 3.98M | 10K | 728K | 10.13M | 19.27M | 20.42M | 24.98M | 10.19M | 0 | 29.68M |
| Other Current Liabilities | 148K | 5.42M | 2.58M | 6.39M | 7M | 13.4M | 13.24M | 35.74M | 44.56M | 40.12M |
| Current Ratio | 7.57x | 8.60x | 11.81x | 6.73x | 12.65x | 6.92x | 8.08x | 13.81x | 11.02x | 11.02x |
| Quick Ratio | 7.57x | 8.60x | 11.81x | 6.73x | 12.65x | 6.92x | 8.08x | 13.81x | 11.02x | 11.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 175.32 |
| Total Non-Current Liabilities | 111.73M | 142.52M | 8.18M | 42.56M | 97.3M | 86.48M | 154.88M | 96.58M | 50.64M | 49.19M |
| Long-Term Debt | 0 | 0 | 0 | 14.51M | 29.87M | 30.32M | 30.7M | 0 | 0 | 13.87M |
| Capital Lease Obligations | 0 | 0 | 1.25M | 426K | 12.08M | 10.88M | 9.38M | 3.99M | 14.77M | 18.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 101.25M | 127.9M | 2M | 2.61M | 3.28M | 3.83M | 4.58M | 1.12M | 363K | 37.12M |
| Total Liabilities | 121.19M | 151.45M | 17M | 65.69M | 133.54M | 139.83M | 224.41M | 163.81M | 107.62M | 98.08M |
| Total Debt | 0 | 0 | 1.89M | 15.78M | 44.34M | 44.33M | 44.96M | 9.49M | 17.52M | 13.87M |
| Net Debt | -67.66M | -63.38M | -90.23M | -120.22M | -394.34M | -294.83M | -481.47M | -870.03M | -610.59M | -545.6M |
| Debt / Equity | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.06x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.30x |
| Interest Coverage | - | - | - | -113.70x | -21.95x | -33.16x | -58.21x | -99.46x | -1061.17x | -1465.53x |
| Total Equity | -47.18M▲ 0% | -69.83M▼ 48.0% | 93.2M▲ 233.5% | 95.46M▲ 2.4% | 346.25M▲ 262.7% | 270.78M▼ 21.8% | 370.93M▲ 37.0% | 793.06M▲ 113.8% | 609.98M▼ 23.1% | 554.32M▲ 0% |
| Equity Growth % | -688.04% | -47.99% | 233.47% | 2.43% | 262.72% | -21.8% | 36.98% | 113.8% | -23.09% | -97.24% |
| Book Value per Share | -3.55 | -5.25 | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | 13.62 | 8.80 | 7.95 |
| Total Shareholders' Equity | -47.18M | -69.83M | 93.2M | 95.46M | 346.25M | 270.78M | 370.93M | 793.06M | 609.98M | 554.32M |
| Common Stock | 5K | 10K | 227K | 266K | 384K | 387K | 550K | 890K | 894K | 899K |
| Retained Earnings | -48.1M | -69.94M | -100.55M | -151.56M | -218.38M | -331.1M | -511.76M | -680.79M | -899.75M | -960.58M |
| Treasury Stock | -837K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 69K | -1.75M | -1.53M | -3.19M | -3.39M | 387K | -1.3M | 119K | -3.5M | -5.28M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCYC Cash Flow Statement
Bicycle Therapeutics plc (BCYC) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.42M | -26.08M | -28.61M | -17.79M | -14.79M | -86.11M | -60.63M | -164.72M | -249.68M | -249.68M |
| Operating CF Margin % | -68.69% | -365.44% | -207.33% | -171.21% | -126.48% | -595.39% | -224.75% | -466.97% | -343.97% | - |
| Operating CF Growth % | 87.44% | -1742.97% | -9.72% | 37.83% | 16.84% | -482.07% | 29.59% | -171.7% | -51.57% | -219.91% |
| Net Income | -16.26M | -21.85M | -30.61M | -51.01M | -66.82M | -112.72M | -180.66M | -169.03M | -218.96M | -219.03M |
| Depreciation & Amortization | 332K | 712K | 960K | 1.28M | 1.41M | 3.69M | 6.55M | 7.17M | 0 | -511.27K |
| Stock-Based Compensation | 515K | 1.02M | 3.08M | 6.51M | 12.08M | 26.78M | 32.48M | 38.08M | 0 | -2.67M |
| Deferred Taxes | 119K | 0 | 0 | -673K | -1.67M | -4.98M | 3.31M | -5.23M | 0 | 1.08M |
| Other Non-Cash Items | 856K | 665K | 5.38M | 751K | 2.14M | 442K | 1.04M | -2.26M | 45.21M | -43.67M |
| Working Capital Changes | 13.02M | -6.63M | -7.43M | 25.35M | 38.06M | 672K | 76.66M | -33.46M | -75.93M | 35.68M |
| Change in Receivables | -1.42M | -400K | 4.91M | -2.15M | 4.54M | -11.35M | -1.2M | -11.95M | 2.9M | 9.45M |
| Change in Inventory | 0 | -2.12M | -2.55M | 4.16M | -4.79M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 67K | -169K | 220K | -663K | 1.2M | 2.56M | 8M | 3.1M | -6.89M | 1.2M |
| Cash from Investing | -1.11M | -1.19M | -1.55M | -1.2M | -2.03M | -18.99M | -2.93M | -1.24M | -2.35M | -2.46M |
| Capital Expenditures | -1.11M | -1.19M | -1.55M | -1.2M | -2.03M | -18.99M | -2.93M | -1.24M | -2.36M | -106.68K |
| CapEx % of Revenue | 54.03% | 16.62% | 11.27% | 11.55% | 17.35% | 131.28% | 10.86% | 3.5% | 3.25% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.49K | -2.35M |
| Cash from Financing | 57.88M | 25.43M | 58.44M | 62.84M | 320.73M | 6.69M | 250.03M | 519.75M | -131K | -143.84K |
| Debt Issued (Net) | 0 | 0 | 0 | 15M | 15M | 0 | 0 | -31.91M | 0 | 43K |
| Equity Issued (Net) | 57.88M | 25.43M | 58.29M | 48.14M | 298.54M | 5.7M | 249.34M | 544.13M | 37.09K | -2.01K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -576K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1K | 1K | 149K | -301K | 7.18M | 989K | 682K | 7.53M | -168.09K | -184.84K |
| Net Change in Cash | 58.26M▲ 0% | -4.28M▼ 107.4% | 28.74M▲ 771.0% | 43.87M▲ 52.7% | 302.69M▲ 589.9% | -99.53M▼ 132.9% | 187.82M▲ 288.7% | 353.1M▲ 88.0% | -251.35M▼ 171.2% | -232.95M▲ 0% |
| Free Cash Flow | -2.53M▲ 0% | -27.26M▼ 978.5% | -30.17M▼ 10.7% | -18.99M▲ 37.1% | -16.82M▲ 11.4% | -105.1M▼ 524.7% | -63.56M▲ 39.5% | -165.96M▼ 161.1% | -252.61M▼ 52.2% | -229.01M▲ 0% |
| FCF Margin % | -122.72% | -382.06% | -218.59% | -182.76% | -143.83% | -726.67% | -235.61% | -470.47% | -348.02% | -360.66% |
| FCF Growth % | 78.04% | -978.48% | -10.65% | 37.06% | 11.4% | -524.69% | 39.53% | -161.12% | -52.21% | -25.51% |
| FCF per Share | -0.19 | -2.05 | -2.73 | -0.99 | -0.67 | -3.54 | -1.79 | -2.85 | -3.65 | -3.65 |
| FCF Conversion (FCF/Net Income) | 0.09x | 1.19x | 0.93x | 0.35x | 0.22x | 0.76x | 0.34x | 0.97x | 1.14x | 1.05x |
| Interest Paid | 0 | 0 | 0 | 378K | 2.52M | 2.79M | 2.75M | 1.37M | 0 | -22K |
| Taxes Paid | 0 | 73K | 117K | 124K | 73K | 2.23M | 562K | 792K | 0 | 0 |
BCYC Key Ratios
Bicycle Therapeutics plc (BCYC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -261.92% | -54.08% | -30.25% | -36.53% | -56.31% | -29.04% | -31.21% | -35.74% |
| Return on Invested Capital (ROIC) | - | - | -663.67% | - | - | - | - | - | - | 1200.55% |
| Gross Margin | -476.02% | -190.93% | -85.06% | -219.05% | 100% | 100% | -480.13% | -390.34% | 100% | -13.26% |
| Net Margin | -789.27% | -306.14% | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -479.18% | -301.66% | -344.95% |
| Debt / Equity | - | - | 0.02x | 0.17x | 0.13x | 0.16x | 0.12x | 0.01x | 0.03x | 0.03x |
| Interest Coverage | - | - | - | -113.70x | -21.95x | -33.16x | -58.21x | -99.46x | -1061.17x | -1465.53x |
| FCF Conversion | 0.09x | 1.19x | 0.93x | 0.35x | 0.22x | 0.76x | 0.34x | 0.97x | 1.14x | 1.05x |
| Revenue Growth | - | 246.41% | 93.4% | -24.72% | 12.58% | 23.65% | 86.52% | 30.76% | 105.77% | 146.85% |
BCYC SEC Filings & Documents
Bicycle Therapeutics plc (BCYC) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCYC Frequently Asked Questions
Bicycle Therapeutics plc (BCYC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bicycle Therapeutics plc (BCYC) reported $63.5M in revenue for fiscal year 2025.
Bicycle Therapeutics plc (BCYC) grew revenue by 105.8% over the past year. This is strong growth.
Bicycle Therapeutics plc (BCYC) reported a net loss of $219.0M for fiscal year 2025.
Dividend & Returns
Bicycle Therapeutics plc (BCYC) has a return on equity (ROE) of -31.2%. Negative ROE indicates the company is unprofitable.
Bicycle Therapeutics plc (BCYC) had negative free cash flow of $229.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More BCYC
Bicycle Therapeutics plc (BCYC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates